Maryam Zarei, MD
Payments from drug & device makers
Across 526 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- GSK$2K
- Genentech USA, Inc.$2K
- AstraZeneca$2K
- Pfizer$943
- Takeda Pharmaceuticals U.S.A., Inc.$529
- plus $5K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 45 | $1,977 |
| GSK | 64 | $1,768 |
| Genentech USA, Inc. | 16 | $1,721 |
| AstraZeneca | 71 | $1,671 |
| Pfizer | 51 | $943 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $529 |
| CSL Behring | 17 | $489 |
| Grifols USA, LLC | 31 | $482 |
| Kaleo, Inc. | 28 | $417 |
| Optinose US, Inc. | 22 | $365 |
| Regeneron Healthcare Solutions, Inc. | 23 | $352 |
| Alk-abello, Inc | 18 | $283 |
| Novartis | 10 | $274 |
| Shire North American Group Inc | 19 | $254 |
| Incyte Corporation | 17 | $225 |
| Genentech, Inc. | 3 | $216 |
| Amgen(2 entities) | 5 | $211 |
| Blueprint Medicines Corporation | 6 | $172 |
| AbbVie(2 entities) | 10 | $167 |
| Pharming Healthcare, Inc. | 5 | $141 |
| Boehringer Ingelheim | 9 | $137 |
| Seqirus USA Inc | 5 | $103 |
| LEO Pharma Inc. | 4 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $89 |
| Biocryst US Sales Co., LLC | 3 | $64 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $52 |
| Octapharma USA, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $18 |
| Organon | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
How this compares
$13,396 in reported general payments places this provider in the 80th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy in Poway
- Ricardo TanLos Angeles$11.2M
- Joshua JacobsWalnut Creek$5.1M
- Warner CarrLaguna Niguel$2.4M
- William BergerMission Viejo$976K
- Robert ZeigerSan Diego$722K
- Bradley ChippsSacramento$712K
- Travis MillerRoseville$277K
- Sarah FieldOrange$271K
- Jonathan TamLos Angeles$222K
- Sandra ChristiansenSan Diego$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.